Being the deregulated BCR/ABL kinase activity the cause of CML, targeting its catalytic domain was the most rationale approach for the rational development of small molecules that inhibit ABL kinase activity. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.